“HEY IS THIS ZAK?”
“-HEAVY BREATHING- WHAT’S YOUR APARTMENT NUMBER?”
** FEELS UNEASY
RKS DESIGN HIGHLIGHTS OF OUR 37TH YEAR. 100K Plus Miles travelled for research studies. 10,000 Plus Hours spent in the war rooms.
50 Plus happy clients. 20 Plus brands came to life
Gamevice Closes $12.5M Series A
LOS ANGELES, PRNewswire -- Gamevice Inc. announces a US$12.5 million Series A co-led by TransLink Capital and California Technology Ventures (CTV). Other notables include BAM Ventures, TYLT Ventures, and Kevin Chou, the former CEO of Kabam and new Gamevice board member. Gamevice Inc. is the creator of an attachable gamepad controller that transforms smart devices into hyper-advanced mobile gaming consoles, currently available online and in the 490 Apple retail stores worldwide.
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its HIV vaccine, PENNVAX®-GP, produced amongst the highest overall levels of immune response rates (cellular and humoral) ever demonstrated in a human study by an HIV vaccine. The vaccine candidate, PENNVAX-GP, consists of a combination of four HIV antigens designed to cover multiple global HIV strains and generate both an antibody (humoral) immune response as well as a T cell (cellular) immune response to both potentially prevent and treat HIV.